Skip Navigation LinksHome > September 2007 - Volume 1 - Issue 3 > Buprenorphine-naloxone Treatment for Pre-release Opioid-depe...
Journal of Addiction Medicine:
doi: 10.1097/ADM.0b013e31814b8880
Original Article

Buprenorphine-naloxone Treatment for Pre-release Opioid-dependent Inmates in Puerto Rico

Garcia, Carmen Albizu MD; Correa, Glorimar Caraballo BS; Viver, Adriana D. Hernandez BS; Kinlock, Timothy W. PhD; Gordon, Michael S. DPA; Avila, Cristobal Antron MD; Reyes, Ivette Colón MD; Schwartz, Robert P. MD

Collapse Box

Abstract

The following study, conducted in Puerto Rico, examined the feasibility of providing daily buprenorphine-naloxone (bup-nx) in prison and on release to 45 male inmates with histories of heroin addiction. Participants were assessed at study entry and at 1 month after release (N = 42; 93.3% follow-up rate). Treatment completers compared with noncompleters had significantly greater reductions in self-reported heroin use, cocaine use, and crime and were less likely to be opioid-positive according to urine drug testing. Despite study limitations, the short-term outcomes of this study suggest that bup-nx may contribute to reductions in readdiction to heroin and in criminal activities among re-entering male prisoners.

© 2007 American Society of Addiction Medicine

    

Login

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.